2 withdrawn, 1 completed. 3 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Withdrawn 2, Completed 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Withdrawn 1 |
Follow exoenzyme C3, Clostridium botulinum: new trials by email Literature Review of exoenzyme C3, Clostridium botulinum trials Research Report on exoenzyme C3, Clostridium botulinum
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Cethrin in Acute Cervical Spinal Cord Injury Cethrin (BA-210), Placebo - Spinal Cord Injury | Phase 2 / Phase 3 | Withdrawn | BioAxone BioSciences, Inc. | 2015-07-01 | 2014-11-26 | |
| A Safety Study for Cethrin (BA-210) in the Treatment of Acute Thoracic and Cervical Spinal Cord Injuries Cethrin - Spinal Cord Injury | Phase 1 / Phase 2 | Completed | Vertex Pharmaceuticals Incorporated | 48 | 2005-02-01 | 2016-04-14 |
| Safety and Efficacy of Cethrin® in Adult Subjects With Acute Cervical Spinal Cord Injury Cethrin® (BA-210), placebo - Acute Cervical Spinal Cord Injury | Phase 2 | Withdrawn | BioAxone BioSciences, Inc. | 2014-01-17 |
Night Blindness, Congenital Stationary, Autosomal Dominant 1 (2) · Paralysis (2) · Paraplegia (2) · Quadriplegia (2) · Spinal Cord Injuries (2) · Wounds and Injuries (2) · Neurologic Manifestations (1)
BioAxone BioSciences, Inc. (2) · Vertex Pharmaceuticals Incorporated (1)
Canada (1) · United States (1)
Michael J. Fehlings, MD, PhD, FRCSC, FACS (1)